[HTML][HTML] Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D'Angelo, J Larkin, JA Sosman… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.gov
Purpose Mucosal melanoma is an aggressive malignancy with a poor response to
conventional therapies. The efficacy and safety of nivolumab (a programmed death-1
checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-
4 checkpoint inhibitor), have not been reported in this rare melanoma subtype.
conventional therapies. The efficacy and safety of nivolumab (a programmed death-1
checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-
4 checkpoint inhibitor), have not been reported in this rare melanoma subtype.
Abstract
Purpose
Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported in this rare melanoma subtype.
ncbi.nlm.nih.gov